PFE Stock 12 Month Forecast $31.56 ▲(24.99% Upside) Based on19Wall Street analysts offering 12 month price targets forPfizerin the last3 months. The average price target is$31.56with a high forecast of$45.00and a low forecast of$25.00. The average price target represents a24.99%change from...
said they're unhappy with how the company handled cost cuts in 2023. Some alleged that Pfizer management provided little transparency around the layoffs and seemed more focused on the company's stock performance than its staff throughout the process. ...
In August, Pfizer’s stock came under fire when the drug maker reported a drop in earnings because of weaker demand for COVID vaccines and antiviral drugs. Even with that lower demand, Pfizer forecast in August full-year earnings of $3.25 to $3.45 a share on revenue of $6...
Explore Pfizer (PFE) dividend history, dividend yield range, next PFE dividend date, and Pfizer stock dividend forecast.
Pictured: Pfizer in Brussels/iStock, Alexandros Michailidis Pfizer’s second-quarter report Tuesday revealed it brought in revenue lower than forecasted as COVID-related sales plummeted more than expected. Looking ahead, the company trimmed the top end of its 2023 revenue range by $1 b...
Looking ahead, the New York-based company maintained its 2023 sales forecast of $67 billion to $71 billion. Pfizer also reiterated its full-year adjusted earnings outlook of $3.25 to $3.45 per share. But Pfizer continues to expect Covid-related sales to decline this year. The company reaffir...
Pfizer (PFE) adaptive stock price forecast & ideologically balanced news. Transparently evaluate AI model performance.
Equities PFE US7170811035 Pharmaceuticals Market Closed -Nyse 04:00:02 2025-03-17 pm EDTAfter market07:35:27 pm 26.05USD+1.28% 26.10+0.21% Mar. 17Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care RoundupDJ ...
What is Pfizer (PFE) stock EPS forecast? Pfizer beatanalysts’ expectations during the last earnings period by33.59%. Pfizer reported earnings of $ 0.63 per share on Feb 4, 2025, while the forecasted EPS was $ 0.4716. Market Open ...
First-Quarter 2023 Revenues from Comirnaty(1)and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty(1)and Paxlovid, Revenues Grew 5% Operationally First-Quarter 2023 Reported Diluted EPS(2)of $0.97, a Year-Over-Year Decline of 29%, and Adjusted Diluted EPS(3)of $1.23, a Yea...